Euroopan unioni -
suomi -
EMA (European Medicines Agency)
lutetium (177lu) chloride billev (previously illuzyce)
billev pharma aps - lutetium (177lu) chloride - radionuklidien kuvantaminen - terapeuttiset radiofarmaseuttiset valmisteet - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
forthyron smak vet. 200 mikrog tabletti
eurovet animal health b.v. - levothyroxine sodium - tabletti - 200 mikrog - levotyroksiininatrium
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
forthyron smak vet. 400 mikrog tabletti
eurovet animal health b.v. - levothyroxine sodium - tabletti - 400 mikrog - levotyroksiininatrium
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
forthyron smak vet. 600 mikrog tabletti
eurovet animal health b.v. - levothyroxine sodium - tabletti - 600 mikrog - levotyroksiininatrium
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
forthyron smak vet. 800 mikrog tabletti
eurovet animal health b.v. - levothyroxine sodium - tabletti - 800 mikrog - levotyroksiininatrium
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
padcev
astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastiset aineet - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.